Detailed Narrative
Commercial Expansion & Strategy
QT Imaging expanded its US commercial team with two new VPs for regional sales, aiming to deepen engagement with imaging centers, clinicians, and enterprise health systems. This direct sales effort complements their exclusive distribution partnership with Ali Imaging (Canon Medical Systems US). Internationally, they are leveraging regional partners in Saudi Arabia (Golf Medical), UAE (Alnagi Medical), and Pakistan (Reinvent Pharma) for capital-efficient market expansion.
Regulatory & Reimbursement Milestones
The company secured SFDA clearance in Saudi Arabia and MAR authorization in Israel, expanding its market access in the Middle East. Domestically, they received two FDA clearances for enhanced scanner configuration and volumetric measurement software. A critical milestone was the AMA approval of a dedicated Category 3 CPT reimbursement code, effective January 1, 2027, which provides a framework for future coverage decisions.
Clinical Evidence & Studies
QT Imaging is actively building a body of clinical evidence. A multisite study demonstrated high reproducibility (<1% variability) of speed of sound measurements. A Mayo Clinic feasibility study showed agreement between their Qscan and MRI findings, leading to a planned 100+ patient follow-up study. Additional studies are evaluating the technology in diagnostic pathways and monitoring treatment response in women receiving neoadjuvant chemotherapy.
Technology & Platform Innovation
The company released software version 4.50, improving spatial resolution for breast acoustic reflection imaging. Collaborations with Ole Medical are focused on productizing the QTR viewer for integrated image visualization and quantitative assessment, while Intelerad provides secure cloud and PACS infrastructure for the QT Precision Pathway platform, supporting future AI-enabled applications.
Operational & Financial Strengthening
QT Imaging successfully completed its first routine FDA inspection with zero Form FDA 483 observations, highlighting its quality management system. The company is relocating its headquarters and manufacturing to a new 22,000 sq ft facility in Petaluma, California, which will more than double its operational space at a 55% lower lease cost per square foot, expanding manufacturing capacity and improving efficiency. They also strengthened their balance sheet with a $10 million public offering and extended their senior secured term loan maturity by two years.
Leadership & Vision
Dr. Julia Albright was appointed Chief Science Officer, bringing extensive experience in medical imaging and AI to align scientific strategy and product innovation. The company's long-term vision extends beyond the breast acoustic CT scanner to building a quantitative breast imaging platform that integrates hardware, software, cloud infrastructure, and AI-enabled clinical applications to enhance personalized breast health management.